Allograft Transplantation
Allograft Transplantation - Related Videos
09:01
Normothermic Ex Vivo Pancreas Perfusion for the Preservation of Pancreas Allografts before Transplantation
0 Views •
Cited by 3 •
2022
Normothermic ex vivo machine perfusion (NEVP) has scarcely been explored for the preservation of pancreas allografts. We present an innovative preservation technique for pancreas allografts before transplantation.
16:15
Mouse Kidney Transplantation: Models of Allograft Rejection
0 Views •
Cited by 17 •
2014
Here, we present a protocol to study the immunology of rejection. The surgical model presented reports a short operating time and a concise technique. Depending on the donor-recipient strain combination, the transplanted kidney may develop acute cellular rejection or chronic allograft damage, defined by interstitial fibrosis and tubular atrophy.
07:15
Orthotopic Hind Limb Transplantation in the Mouse
0 Views •
Cited by 24 •
2016
This novel model for orthotopic hind limb transplantation in the mouse, applying a non-suture cuff technique for super-microvascular anastomosis, provides a powerful tool for in vivo mechanistic immunological research related to vascularized composite allotransplantation (VCA).
14:03
Orthotopic Hind-Limb Transplantation in Rats
0 Views •
Cited by 21 •
2010
Here we describe the orthotopic rat hind-limb transplantation procedure, which seems to be the gold standard in vivo model for composite tissue allotransplantation research.
07:59
Murine Full-thickness Skin Transplantation
0 Views •
Cited by 41 •
2017
Murine full-thickness skin transplantation is a well-established model to study rejection in an alloimmune setting. Here, we provide a tutorial of each step involved in performing a BALB/c-->C57BL/6 full-thickness skin transplant.
FAQs
Rejection begins when recipient lymphocytes identify donor antigens as foreign rather than accepting them as self. Polymorphic HLA molecules are especially important because their genetic variation creates differences between individuals that can be detected by the recipient immune system. This recognition activates an immune response, making antigen recognition the central biological barrier to successful allograft transplantation.
Because HLA genes vary among individuals, donor and recipient cells may display different HLA patterns. Those differences provide the immune system with prominent markers of genetic nonidentity. HLA typing compares these patterns before transplantation, allowing researchers and clinicians to estimate how strongly the recipient may recognize the graft and incorporate that information into donor selection.
HLA typing describes donor-recipient antigen patterns, whereas antibody assessment contributes another compatibility measure. Used together, these evaluations help estimate rejection risk more comprehensively than either genetic comparison alone. The resulting information can guide donor selection and support decisions about how closely the recipient’s immune response may need to be controlled after transplantation.
Immunosuppressive therapy helps limit the lymphocyte-mediated response directed against donor antigens. It does not change the underlying genetic differences between donor and recipient; instead, it acts on the immune reaction those differences can provoke. In transplantation practice, immunosuppression therefore complements compatibility testing, which estimates risk before the graft is placed, rather than replacing donor-recipient assessment.
Donor selection can incorporate compatibility testing that includes HLA typing and antibody assessment. HLA results identify relevant donor-recipient antigen differences, while antibody results add information used to estimate rejection risk. Together, these genetic and immune measurements help identify a donor whose graft may present a more manageable compatibility profile for the intended recipient.
Genetics contributes a structured sequence: compare donor and recipient HLA types, assess antibodies, estimate rejection risk, and use those findings to guide donor selection. This workflow connects molecular variation among individuals with a practical transplantation decision. It also helps frame immunosuppressive planning, because the potential immune challenge is anticipated rather than considered only after rejection develops.
Allograft transplantation provides a direct setting for studying how inherited variation influences immune recognition between individuals. Compatibility testing links HLA differences and antibody findings to estimated rejection risk, while treatment seeks to limit the resulting immune response. Research can use this framework to investigate tolerance and advance personalized immunosuppression tailored to compatibility information.